Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00

Affimed (NASDAQ:AFMD) had its target price decreased by stock analysts at Stifel Nicolaus from $5.00 to $4.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective would suggest a potential upside of 9.59% from the stock’s previous close.

Several other research firms also recently commented on AFMD. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research note on Monday, September 9th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Affimed in a research report on Friday. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Affimed Price Performance

Shares of AFMD stock opened at $3.65 on Friday. Affimed has a 12-month low of $2.92 and a 12-month high of $8.95. The firm has a 50 day moving average price of $3.50 and a two-hundred day moving average price of $4.54. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71.

Affimed (NASDAQ:AFMD) last released its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $1.67 million. Research analysts predict that Affimed will post -4.25 earnings per share for the current year.

Institutional Investors Weigh In On Affimed

Institutional investors and hedge funds have recently bought and sold shares of the company. Choreo LLC acquired a new position in shares of Affimed in the 2nd quarter valued at approximately $54,000. FMR LLC increased its stake in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the last quarter. Finally, Intellectus Partners LLC increased its stake in shares of Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the last quarter. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.